Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2025 · first_quarter · 1T
HOPPS separate payment for diagnostic radiopharmaceuticals
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2025 · first_quarter · Q1
Source: Senate LDA
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Legislation (H.R. 1199 and S.1544) on HOPPS separate payment for diagnostic radiopharmaceuticals Medicare 2025 Hospital Prospective Payment System proposal for separate payment for diagnostic radiopharmaceuticals above $630/day cost threshold
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Legislation (H.R. 1199 and S.1544) on HOPPS separate payment for diagnostic radiopharmaceuticals Medicare 2025 Hospital Prospective Payment System proposal for separate payment for diagnostic radiopharmaceuticals above $630/day cost threshold
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. HR 1199)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharmaceuticals
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharmaceuticals
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
Veterans’ Prostate Cancer Treatment and Research Act
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Prostate cancer screening, diagnosis, and treatment in Veterans Healthcare System H.R. 4880 (Veterans Prostate Cancer Treatment and Research Act)
Food and Drug Amendments of 2022
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
FDA user fee reauthorization H.R. 7667, S. 4348; and S. 4333 (regulatory status for imaging contrast agents)
Food and Drug Amendments of 2022
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R. 7667, S. 4348; and S. 4333 - Regulatory status for imaging contrast agents
Food and Drug Amendments of 2022
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
FDA user fee reauthorization H.R. 7667, S. 4348; and S. 4333 (regulatory status for imaging contrast agents)
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharmaceuticals
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharmaceuticals
H.R. 7667, S. 4348; and S. 4333 - Regulatory status for imaging contrast agents
FDA user fee reauthorization H.R. 7667, S. 4348; and S. 4333 (regulatory status for imaging contrast agents)
FDA user fee reauthorization H.R. 7667, S. 4348; and S. 4333 (regulatory status for imaging contrast agents)
FDA user fee reauthorization H.R. 7667, S. 4348; and S. 4333 (regulatory status for imaging contrast agents)
H.R. 7667, S. 4348; and S. 4333 - Regulatory status for imaging contrast agents
FDA user fee reauthorization H.R. 7667, S. 4348; and S. 4333 (regulatory status for imaging contrast agents)
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
Veterans’ Prostate Cancer Treatment and Research Act
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Prostate cancer screening, diagnosis, and treatment in Veterans Healthcare System H.R. 4880 (Veterans Prostate Cancer Treatment and Research Act)
Veterans’ Prostate Cancer Treatment and Research Act
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
Prostate cancer screening, diagnosis, and treatment in Veterans Healthcare System H.R. 4880 (Veterans Prostate Cancer Treatment and Research Act)
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
HR 3772 Medicare Diagnostic Radiopharmaceutical Equity Act; and Onshoring Pharmaceutical Manufacturing
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
HR 3772 - HOPPS reimbursement for high precision diagnostic radiopharmacueticals; and Pharma manufacturing onshoring
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
HR 3772 Medicare Diagnostic Radiopharmaceutical Equity Act Onshoring Pharmaceutical Manufacturing
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
HR 3772 - HOPPS reimbursement for high precision diagnostic radiopharmacueticals; and Pharma manufacturing onshoring
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
HR 3772 Medicare Diagnostic Radiopharmaceutical Equity Act; and Onshoring Pharmaceutical Manufacturing
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R. 3772 Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R. 3772 Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: LANTHEUS HOLDINGS, INC. · Firm: LANTHEUS HOLDINGS, INC.
H.R. 3772 Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
HOPPS separate payment for diagnostic radiopharmaceuticals
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2024 · fourth_quarter · Q4
Medicare 2025 Hospital Prospective Payment System proposal for separate payment for diagnostic radiopharmaceuticals above $630/day cost threshold
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2024 · third_quarter · Q3
Legislation (H.R. 1199 and S.1544) on HOPPS separate payment for diagnostic radiopharmaceuticals Medicare 2025 Hospital Prospective Payment System proposal for separate payment for diagnostic radiopharmaceuticals above $630/day cost threshold
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2024 · first_quarter · 1A
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2024 · second_quarter · Q2
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2024 · first_quarter · Q1
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2023 · fourth_quarter · Q4
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2023 · third_quarter · Q3
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2023 · second_quarter · Q2
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2023 · second_quarter · Q2
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2023 · first_quarter · Q1
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. HR 1199)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2022 · fourth_quarter · Q4
H.R. 7667, S. 4348; and S. 4333 - Regulatory status for imaging contrast agents
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2022 · third_quarter · Q3
FDA user fee reauthorization H.R. 7667, S. 4348; and S. 4333 (regulatory status for imaging contrast agents)
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2022 · second_quarter · Q2
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
FDA user fee reauthorization H.R. 7667, S. 4348; and S. 4333 (regulatory status for imaging contrast agents)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2022 · first_quarter · Q1
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
Prostate cancer screening, diagnosis, and treatment in Veterans Healthcare System H.R. 4880 (Veterans Prostate Cancer Treatment and Research Act)
Possible legislation to clarify FDA regulatory status for imaging contrast agents
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2021 · fourth_quarter · Q4
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
Reliable supply and U.S. production of radioactive and enriched stable isotopes Conversion of medical isotope production to non-Highly Enriched Uranium sources Availability of High-Assay Low Enriched Uranium for medical radioisotope production
Prostate cancer screening, diagnosis, and treatment in Veterans Healthcare System H.R. 4880 (Veterans Prostate Cancer Treatment and Research Act)
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2021 · third_quarter · Q3
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharamceuticals
Prostate cancer screening, diagnosis, and treatment in Veterans Healthcare System H.R. 4880 (Veterans Prostate Cancer Treatment and Research Act)
Reliable supply and U.S. production of radioactive and enriched stable isotopes Conversion of medical isotope production to non-Highly Enriched Uranium sources Availability of High-Assay Low Enriched Uranium for medical radioisotope production
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2021 · second_quarter · Q2
Facilitating Innovative Nuclear Diagnostics Act (no bill number yet)
Conversion of medical isotope production to non-Highly Enriched Uranium sources U.S. production of radioactive and enriched stable isotopes
Prostate cancer screening and diagnosis in Veterans Healthcare system
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2021 · second_quarter · RA
Hospital Outpatient Prospective Payment System reimbursement for diagnostic radiopharmaceuticals Veterans Administration prostate cancer care Domestic production of medical radioisotopes Domestic pharmaceutical manufacturing
Hospital Outpatient Prospective Payment System reimbursement for diagnostic radiopharmaceuticals Veterans Administration prostate cancer care Domestic production of medical radioisotopes Domestic pharmaceutical manufacturing
Hospital Outpatient Prospective Payment System reimbursement for diagnostic radiopharmaceuticals Veterans Administration prostate cancer care Domestic production of medical radioisotopes Domestic pharmaceutical manufacturing
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2021 · first_quarter · Q1
Conversion of medical isotope production to non-Highly Enriched Uranium sources U.S exports of Highly Enriched Uranium
Facilitating Innovative Nuclear Diagnostics Act (no bill number yet) HCPCS code Q9969 (Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose)
On-shoring pharmaceutical manufacturing
Filing targets: Centers For Medicare and Medicaid Services (CMS), Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2020 · fourth_quarter · Q4
HR 3772 Medicare Diagnostic Radiopharmaceutical Equity Act; and Onshoring Pharmaceutical Manufacturing
Pharma manufacturing onshoring
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2020 · third_quarter · Q3
Pharma manufacturing onshoring
HR 3772 Medicare Diagnostic Radiopharmaceutical Equity Act; and Onshoring Pharmaceutical Manufacturing
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2020 · second_quarter · RA
HR 3772 - HOPPS reimbursement for high precision diagnostic radiopharmacueticals; and Pharma manufacturing onshoring
HR 3772 - HOPPS reimbursement for high precision diagnostic radiopharmacueticals; and Pharma manufacturing onshoring
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2020 · second_quarter · Q2
HR 3772 Medicare Diagnostic Radiopharmaceutical Equity Act Onshoring Pharmaceutical Manufacturing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2020 · first_quarter · Q1
AMIPA High Enriched Uranium Export Sunset Certification
H.R. 3772 Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2019 · fourth_quarter · Q4
H.R. 3772 Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
AMIPA High Enriched Uranium Export Sunset Certification
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2019 · third_quarter · Q3
AMIPA High Enriched Uranium Export Sunset Certification
H.R. 3772 Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2019 · second_quarter · Q2
Department of Energy Cooperative Agreements for Domestic Production of Mo-99 High Enriched Uranium Export Certification
Medicare Diagnostic Radiopharmaceutical Payment Equity legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2019 · first_quarter · 1A
Department of Energy Cooperative Agreements for Domestic Production of Mo-99
Medicare Diagnostic Radiopharmaceutical Payment Equity legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS HOLDINGS, INC. via LANTHEUS HOLDINGS, INC.
2019 · first_quarter · RR
Medicare Diagnostic Radiopharmaceutical Payment Equity, Medicare Hospital Outpatient Prospective Payment System, Department of Energy/NNSA Cooperative Agreements for Domestic Production of Mo-99
Medicare Diagnostic Radiopharmaceutical Payment Equity, Medicare Hospital Outpatient Prospective Payment System, Department of Energy/NNSA Cooperative Agreements for Domestic Production of Mo-99
Medicare Diagnostic Radiopharmaceutical Payment Equity, Medicare Hospital Outpatient Prospective Payment System, Department of Energy/NNSA Cooperative Agreements for Domestic Production of Mo-99
Filing targets: Centers For Medicare and Medicaid Services (CMS), Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
On-shoring pharmaceutical manufacturing
Filing targets: Centers For Medicare and Medicaid Services (CMS), Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE